Zobrazeno 1 - 10
of 234
pro vyhledávání: '"SGLT-2i"'
Publikováno v:
The Egyptian Heart Journal, Vol 76, Iss 1, Pp 1-9 (2024)
Abstract Background In heart failure with reduced ejection fraction (HFrEF), sodium–glucose co-transporter inhibitors (SGLT-2i) have persistently shown cardiovascular benefits through different trials. However, their impact on ventricular remodelin
Externí odkaz:
https://doaj.org/article/b77969f749b14fe195bf9f84458a67a8
Autor:
Brijendra Kumar Srivastava, Ranjit Mohan Anjana, Anandakumar Amutha, Muthu Ramuu, Manoharan Sriraam, Viswanathan Mohan
Publikováno v:
Journal of Diabetology, Vol 15, Iss 1, Pp 119-122 (2024)
Background: Continuous subcutaneous insulin infusion (CSII) pump has shown good outcomes in patients with both type 1 and type 2 diabetes mellitus. Here, we present an individual with type 2 diabetes and obesity who was on a high dosage of insulin an
Externí odkaz:
https://doaj.org/article/a3cd14742b7a4312915fc4be64ab19c5
Autor:
Zhengxi Zhou, Xiaotian Yao
Publikováno v:
Heliyon, Vol 10, Iss 12, Pp e33306- (2024)
Background: Dapagliflozin possesses the capacity to cure a wide range of diseases, however, there are many adverse events (AEs) that have not yet been acknowledged or recorded. Aim: Safety assessment of dapagliflozin based on the Food and Drug Admini
Externí odkaz:
https://doaj.org/article/f5263c19a33a43079f6575c5801a7ea2
Autor:
Francesca Cinti, Lucia Leccisotti, Gian Pio Sorice, Umberto Capece, Domenico D’Amario, Margherita Lorusso, Shawn Gugliandolo, Cassandra Morciano, Andrea Guarneri, Maria Angela Guzzardi, Teresa Mezza, Amedeo Capotosti, Luca Indovina, Pietro Manuel Ferraro, Patricia Iozzo, Filippo Crea, Alessandro Giordano, Andrea Giaccari
Publikováno v:
Cardiovascular Diabetology, Vol 22, Iss 1, Pp 1-10 (2023)
Abstract Objective We recently demonstrated that treatment with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) leads to an increase in myocardial flow reserve in patients with type 2 diabetes (T2D) with stable coronary artery disease (CAD). The
Externí odkaz:
https://doaj.org/article/4edb3dd0fd3b4c709f3b58ee9f7fbb6e
Autor:
Anna Simanenkova, Oksana Fuks, Natalya Timkina, Alina Islamova, Dina Sufieva, Оlga Kirik, Dmitrii Korzhevskii, Timur Vlasov, Tatiana Karonova
Publikováno v:
Frontiers in Bioscience-Landmark, Vol 29, Iss 7, p 265 (2024)
Background: Acute and chronic brain damage in type 2 diabetes mellitus (DM) determines the need to investigate the neuroprotective potential of glucose-lowering drugs. The purpose was to directly compare the neuroprotective effects of glucagon-like p
Externí odkaz:
https://doaj.org/article/0f3cb175050746a48a1ef46b02b62bd7
Autor:
Michele Correale, Elena‐Laura Antohi, Riccardo M. Inciardi, Pietro Mazzeo, Stefano Coiro, Shiro Ishihara, Renata Petroni, Francesco Monitillo, Marta Leone, Marco Triggiani, Chaudhry M.S. Sarwar, Hans‐Dirk Dungen, Khawaja M. Talha, Natale D. Brunetti, Javed Butler, Savina Nodari, Master Program Group on Drug Development for Heart Failure
Publikováno v:
ESC Heart Failure, Vol 10, Iss 3, Pp 2066-2073 (2023)
Abstract Aims Sodium‐glucose cotransporter type 2 inhibitors (SGLT‐2i) represent a unique class of anti‐hyperglycaemic agents for type 2 diabetes mellitus that selectively inhibit renal glucose reabsorption, thereby increasing urinary excretion
Externí odkaz:
https://doaj.org/article/de59c9a117ce41d4beb61fc436b157b3
Autor:
Irene Caruso, Ludovico Di Gioia, Sergio Di Molfetta, Angelo Cignarelli, Suetonia Cressida Palmer, Patrizia Natale, Giovanni F.M. Strippoli, Sebastio Perrini, Annalisa Natalicchio, Luigi Laviola, Francesco Giorgino
Publikováno v:
EClinicalMedicine, Vol 64, Iss , Pp 102181- (2023)
Summary: Background: Innovative GLP-1 receptor agonist (GLP-1RA)-based treatment strategies—such as tirzepatide, GLP-1RA plus basal insulin fixed-ratio combinations [FRC], GLP-1RA plus sodium glucose cotransporter-2 inhibitors [SGLT-2i] combination
Externí odkaz:
https://doaj.org/article/cafd11fbb40d4d189cf78ac148f5cf88
Publikováno v:
Frontiers in Endocrinology, Vol 14 (2023)
AimThis study aims to assess the association between sodium–glucose cotransporter type-2 inhibitor (SGLT-2i) treatment and muscle atrophy in patients with type 2 diabetes mellitus (T2DM).MethodsWe searched six databases from 1 January 2012 to 1 May
Externí odkaz:
https://doaj.org/article/44452fc044ff4676957895455a2711e2
Autor:
Konstantinos Katogiannis, John Thymis, Foteini Kousathana, George Pavlidis, Emmanouil Korakas, Aikaterini Kountouri, Konstantinos Balampanis, Vasiliki Prentza, Gavriella Kostelli, Helen Michalopoulou, Damianos Tsilivarakis, Vaia Lambadiari, Ignatios Ikonomidis
Publikováno v:
Medicina, Vol 60, Iss 3, p 395 (2024)
Background and Objectives: Glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter-2 inhibitors (SGLT-2i) are cardioprotective drugs. We investigated their effects on left atrial function, a major determinant of cardiac d
Externí odkaz:
https://doaj.org/article/cb7f66ff4c944624851250bc34bcf33b
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.